Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK-Results based on the Women's Health Initiative randomised controlled trial

Bone

Volumn 42, Issue 2, 2008, Pages 294-306

  Lekander, Ingrid ^a   Borgström, Fredrik ^a,b   Ström, Oskar ^a   Zethraeus, Niklas ^c   Kanis, John A ^d  

^a i3 Innovus ^*  (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

HT; Hysterectomy; Osteoporosis; WHI

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CONJUGATED ESTROGEN; ESTROGEN; ESTROGEN PLUS PROGESTIN; HORMONE; MEDROXYPROGESTERONE ACETATE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; FRAGILITY FRACTURE; HIGH RISK POPULATION; HIP FRACTURE; HORMONAL THERAPY; HYSTERECTOMY; ISCHEMIC HEART DISEASE; MORTALITY; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RANDOMIZATION; STROKE; SWEDEN; SYMPTOM; UNITED KINGDOM; UNITED STATES; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; WRIST FRACTURE;

COST-BENEFIT ANALYSIS; ENGLAND; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; MODELS, ECONOMIC; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SWEDEN; TREATMENT OUTCOME; UNITED STATES;

EID: 38049155961     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.09.059     Document Type: Article

References (102)

1. Banks E., Beral V., Reeves G., Balkwill A., and Barnes I. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 291 (2004) 2212-2220
2. SBU Behandling med östrogen Stockholm: Statens beredning för medicinsk utvärdering (SBU); 1996.
3. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
4. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-4127
5. Colditz G.A., Hankinson S.E., Hunter D.J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332 (1995) 1589-1593
6. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
7. Stanford J.L., Weiss N.S., Voigt L.F., Daling J.R., Habel L.A., and Rossing M.A. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274 (1995) 137-142
8. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280 (1998) 605-613
9. Jackson R.D., Wactawski-Wende J., LaCroix A.Z., et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res 21 (2006) 817-828
10. Menon U., Burnell M., Sharma A., et al. Decline in use of hormone therapy among postmenopausal women in the United Kingdom. Menopause 14 (2007) 462-467
11. Zethraeus N., Borgstrom F., Jonsson B., and Kanis J. Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial. Int J Technol Assess Health Care 21 (2005) 433-441
12. Zethraeus N., F.B., B.J., and J.K. A reassessment of the cost-effectiveness of hormone replacement therapy in Sweden-results based on the Women's Health Initiative randomised controlled trial. Working Paper Series in Economics and Finance at the Stockholm School of Economics, 2004. Working paper vol. 571 (2004)
13. Lothgren M., and Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 9 (2000) 623-630
14. Borgstrom F., Johnell O., Jonsson B., Zethraeus N., and Sen S.S. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34 (2004) 1064-1071
15. Kanis J.A., Johnell O., Gullberg B., et al. Evidence for the efficacy of drugs affecting bone metabolism in the prevention of hip fracture. British Medical Journal 305 (1992) 1124-1128
16. Bagger Y.Z., Tanko L.B., Alexandersen P., et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 34 (2004) 728-735
17. Bagger Y.Z., Tanko L.B., Alexandersen P., Ravn P., and Christiansen C. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33 (2003) 301-307
18. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296 (2006) 2927-2938
19. Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004) 1189-1199
20. De Laet C.E., van Hout B.A., Burger H., Hofman A., and Pols H.A. Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 315 (1997) 221-225
21. Kanis J.A., Johnell O., Oden A., Jonsson B., Dawson A., and Dere W. Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11 (2000) 120-127
22. Hadji P., Gottschalk M., Ziller V., Kalder M., Jackisch C., and Wagner U. Bone mass and the risk of breast cancer: the influence of cumulative exposure to oestrogen and reproductive correlates. Results of the Marburg breast cancer and osteoporosis trial (MABOT). Maturitas 56 (2007) 312-321
23. Zhang Y., Kiel D.P., Kreger B.E., et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 336 (1997) 611-617
24. Adami H.O., Zack M., Kressner U., et al. Hip fractures in women with breast cancer. Am J Epidemiol 132 (1990) 877-883
25. Cauley J.A., Song J., Dowsett S.A., Mershon J.L., and Cummings S.R. Risk factors for breast cancer in older women: the relative contribution of bone mineral density and other established risk factors. Breast Cancer Res Treat 102 (2007) 181-188
26. Gujarati D.N. Basic Econometrics (1995), McGraw Hill, Singapore
27. Kiefer N. Economic duration data and hazard functions. J Econ Lit 26 (1998) 646-679
28. Statistics Sweden. Sweden's Statistical Databases. http://www.scb.se/eng/databaser/ssd.asp. Cited: 2006-11-12.
29. National Statistics Online. www.statistics.gov.uk. Cited 2006-10-12.
30. National center for health statistics. http://www.cdc.gov/nchs/. Cited 2006-08-10.
31. Parker M.J., and Anand J.K. What is the true mortality of hip fractures?. Public Health 105 (1991) 443-446
32. Kanis J.A., Oden A., Johnell O., De Laet C., Jonsson B., and Oglesby A.K. The components of excess mortality after hip fracture. Bone 32 (2003) 468-473
33. Kanis J.A., Oden A., Johnell O., De Laet C., and Jonsson B. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15 (2004) 108-112
34. Center J.R., Nguyen T.V., Schneider D., Sambrook P.N., and Eisman J.A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353 (1999) 878-882
35. Johnell O., Kanis J.A., Oden A., et al. Mortality after osteoporotic fractures. Osteoporos Int 15 (2004) 38-42
36. Tengs T.O., and Lin T.H. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 21 (2003) 191-200
37. Bharmal M., and Thomas III J. Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health 9 (2006) 262-271
38. Burstrom K., Johannesson M., and Diderichsen F. Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy 55 (2001) 51-69
39. Kind P., Dolan P., Gudex C., and Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. Br Med J 316 (1998) 736-741
40. Zethraeus N., Johannesson M., Henriksson P., and Strand R.T. The impact of hormone replacement therapy on quality of life and willingness to pay. Br J Obstet Gynaecol 104 (1997) 1191-1195
41. Strom O., Borgstrom F., Sen S.S., et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries-an economic evaluation based on the fracture intervention trial. Osteoporos Int 18 (2007) 1047-1061
42. Armstrong K., Chen T.M., Albert D., Randall T.C., and Schwartz J.S. Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol 98 (2001) 996-1003
43. Kim C., and Kwok Y.S. Decision analysis of hormone replacement therapy after the Women's Health Initiative. Am J Obstet Gynecol 189 (2003) 1228-1233
44. Zethraeus N., Ben Sedrine W., Caulin F., et al. Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 13 (2002) 841-857
45. Field C.S., Ory S.J., Wahner H.W., Herrmann R.R., Judd H.L., and Riggs B.L. Preventive effects of transdermal 17 beta-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol 168 (1993) 114-121
46. Lee S.J., and Kanis J.A. An association between osteoporosis and premenstrual symptoms and postmenopausal symptoms. Bone Miner 24 (1994) 127-134
47. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 (2003) 3243-3253
48. Beral V., Bull D., Green J., and Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369 (2007) 1703-1710
49. Rossouw J.E., Prentice R.L., Manson J.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297 (2007) 1465-1477
50. Apotekets totala försäljning av humanläkemedel 2005. Bokstavsordning. Apoteket www.apoteket.se
51. Borgstrom F., Johnell O., Kanis J.A., Jonsson B., and Rehnberg C. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17 (2006) 1459-1471
52. Singer B.R., McLauchlan G.J., Robinson C.M., and Christie J. Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 80 (1998) 243-248
53. Melton III L.J., Crowson C.S., and O'Fallon W.M. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9 (1999) 29-37
54. Kanis J.A., Johnell O., Oden A., et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11 (2000) 669-674
55. Cooper C., Atkinson E.J., Kotowicz M., O'Fallon W.M., and Melton III L.J. Secular trends in the incidence of postmenopausal vertebral fractures. Calcif Tissue Int 51 (1992) 100-104
56. Centre for Epidemiology at the National Board of Health and Welfare, Sweden.
57. Cancer Statistics Registrations - Registrations of Cancer Diagnosed in 1998, England, Series MB1 no29. London: Office for National Statistics; 2002.
58. CINA+ online (North American Association of Central Cancer Registers). http://www.naaccr.org/scripts/servlet.dll/cinap/CiNAGateRouter. Cited 2006-06-02.
59. Kannel W., Wolf P., and Garrison R. The Framingham study: an epidemiological investigation of cardiovascular disease (1987), US Department of Commerce National Technical Information Service, Springfield
60. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
61. General Household survey, Office for National Statistics "Focus on Health Data"-Updated Feb 2006 at http://www.statistics.gov.uk/statbase/Product.asp?vlnk=12985. 2006-12-06. 2006.
62. Sproston K, Primatesta P. National Statistics, Health survey for England, risk factors for cardiovascular disease, vol. 2.
63. NHANES (http://www.cdc.gov/nchs/nhanes.htm). Cited 2006-05-20.
64. Rothwell P.M., Coull A.J., Giles M.F., et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 363 (2004) 1925-1933
65. Williams G.R. Incidence and characteristics of total stroke in the United States. BMC Neurol 1 2 (2001)
66. Silverstein M.D., Heit J.A., Mohr D.N., Petterson T.M., O'Fallon W.M., and Melton III L.J. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158 (1998) 585-593
67. Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). Available at www.mortality.org (data downloaded on [2005-10-10]).
68. Oden A., Dawson A., Dere W., Johnell O., Jonsson B., and Kanis J.A. Lifetime risk of hip fractures is underestimated. Osteoporos Int 8 (1998) 599-603
69. Surveillance, Epidemiology, and End Results, National Cancer Institute, http://seer.cancer.gov/. Cited 2005-11-07.
70. Borgstrom F., Zethraeus N., Johnell O., et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17 (2006) 637-650
71. Zethraeus N., and Gerdtham U.G. Estimating the costs of hip fracture and potential savings. Int J Technol Assess Health Care 14 (1998) 255-267
72. Zethraeus N., Stromberg L., Jonsson B., Svensson O., and Ohlen G. The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 68 (1997) 13-17
73. Stevenson M., Davis S., and Kanis J. The hospitalization costs and outpatient costs of fragility fractures. Women's Health Med. (2006) 149-151
74. Lawrence T.M., White C.T., Wenn R., and Moran C.G. The current hospital costs of treating hip fractures. Injury 36 (2005) 88-91 [discussion 92]
75. Netten A, Rees T, Harrison G. Unit Costs of health and Social Care. University of Kent: Personal Social Services Research Unit; 2002.
76. Gabriel S.E., Tosteson A.N., Leibson C.L., et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 13 (2002) 323-330
77. MetLife Mature MArket Institute. 2003.
78. Hutton J., Brown R., Borowitz M., Abrams K., Rothman M., and Shakespeare A. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 9 Suppl 2 (1996) 8-22
79. Warren J.L., Brown M.L., Fay M.P., Schussler N., Potosky A.L., and Riley G.F. Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol 20 (2002) 307-316
80. Ross P., Heron J., and Cunningham D. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer 32 Suppl 5 (1996) S13-S17
81. Brown M.L., Riley G.F., Potosky A.L., and Etzioni R.D. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 37 (1999) 1249-1259
82. Zethraeus N. A computer model to analyse the cost-effectiveness of hormone replacement therapy : a revised version. SSE/EFI working paper series in economics and finance, 368. Stockholm; 2000.
83. Daly E., Vessey M.P., Barlow D., Gray A., McPherson K., and Roche M. Hormone replacement therapy in a risk-benefit perspective. Maturitas 23 (1996) 247-259
84. Sanderson C., and Kubin M. Prevention of coronary heart disease through treatment of infection with Chlamydia pneumoniae? Estimation of possible effectiveness and costs. Health Care Manag Sci 4 (2001) 269-279
85. Russell M.W., Huse D.M., Drowns S., Hamel E.C., and Hartz S.C. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 81 (1998) 1110-1115
86. Ashraf T., Hay J.W., Pitt B., et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 78 (1996) 409-414
87. Ghatnekar O., Persson U., Glader E.L., and Terent A. Cost of stroke in Sweden: an incidence estimate. Int J Technol Assess Health Care 20 (2004) 375-380
88. Patel A., Knapp M., Perez I., Evans A., and Kalra L. Alternative strategies for stroke care: cost-effectiveness and cost-utility analyses from a prospective randomized controlled trial. Stroke 35 (2004) 196-203
89. Taylor T.N., Davis P.H., Torner J.C., Holmes J., Meyer J.W., and Jacobson M.F. Lifetime cost of stroke in the United States. Stroke 27 (1996) 1459-1466
90. Medpar inpatient hospital data for fiscal year 2003 (2004 update).
91. Zethraeus N., Borgström F., Johnell O., Kanis J., and Jönsson B. Costs and quality of life associated with osteoporosis related fractures-results from a Swedish survey. Working Paper Series in Economics and Finance vol. 512 (2002)
92. Liljegren G., Karlsson G., Bergh J., and Holmberg L. The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial. Ann Oncol 8 (1997) 757-763
93. Lindgren P, Glader EL, Jonsson B. Utility loss and indirect costs after stroke in Sweden. Value Health, 2006;9:A330-A330 [NOV-DEC 2006].
94. Zethraeus N., Molin T., Henriksson P., and Jonsson B. Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med 246 (1999) 151-159
95. Ekman M., Zethraeus N., Dahlstrom U., and Hoglund C. Cost-effectiveness of bisoprolol in chronic heart failure. Lakartidningen 99 (2002) 646-650
96. Meltzer D., Egleston B., Stoffel D., and Dasbach E. Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus. Med Care 38 (2000) 679-685
97. Jonsson B., Christiansen C., Johnell O., Hedbrandt J., and Karlsson G. Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103 (1996) 30-38
98. Ström O, Borgstrom F, Zethraeus N, et al. Long term costs and quality of life associated with osteoporosis related fractures in sweden. Acta Orthopaedica (September) 2007, Accepted for publication.
99. Lidgren M., Wilking N., Jönsson B., and Rehnberg C. Health related quality of life in different states of breast cancer. Qual Life Res 16 (2007) 1073-1081
100. Jorgensen H.S., Nakayama H., Raaschou H.O., Vive-Larsen J., Stoier M., and Olsen T.S. Outcome and time course of recovery in stroke. Part II: Time course of recovery. The Copenhagen Stroke Study. Arch Phys Med Rehabil 76 (1995) 406-412
101. van Stel H.F., and Buskens E. Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. Health Qual Life Outcomes 4 20 (2006)
102. Hoeymans N., van Lindert H., and Westert G.P. The health status of the Dutch population as assessed by the EQ-6D. Qual Life Res 14 (2005) 655-663